{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-168524","form_type":"8-K","ticker":null,"cik":"0001718852","company_name":"Prometheus Biosciences, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.207249+00:00","generated_at":"2026-06-13T22:54:43.849640+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Merck completes acquisition of Prometheus Biosciences for $200/share","bullets":["Merger closed June 16, 2023; Prometheus stockholders received $200 cash per share.","Prometheus becomes wholly owned subsidiary of Merck; trading suspended, delisting from Nasdaq initiated.","All prior directors and executive officers replaced by Merck designees; charter and bylaws amended."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-168524","json":"https://secwatch.observer/filing/0001193125-23-168524.json","markdown":"https://secwatch.observer/filing/0001193125-23-168524.md","text":"https://secwatch.observer/filing/0001193125-23-168524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/d466468d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:54:43.849640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"066bfa630f","claim":"Martin Hendrix, Ph.D. resigned as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"each of the directors of Prometheus (Mark C. McKenna, Helen C. Adams, Fred Hassan, Martin Hendrix, Ph.D., James Laur, Joseph C. Papa, Judith L. Swain, M.D. and Mary Szela) resigned from the board of directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"141b3076e9","claim":"Rita Karachun was appointed as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"At the Effective Time, Jon Filderman, Rita Karachun and Aaron Rosenberg, each a director of Merger Sub immediately prior to the Effective Time, became directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"51e0419d13","claim":"Keith W. Marshall, Ph.D. departed as Executive Officer at Prometheus Biosciences, Inc..","evidence_excerpt":"Mark C. McKenna, Keith W. Marshall, Ph.D. and Mark Stenhouse ceased to be executive officers of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"6cd9edfc35","claim":"Aaron Rosenberg was appointed as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"At the Effective Time, Jon Filderman, Rita Karachun and Aaron Rosenberg, each a director of Merger Sub immediately prior to the Effective Time, became directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8d8fb1f91e","claim":"Mary Szela resigned as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"each of the directors of Prometheus (Mark C. McKenna, Helen C. Adams, Fred Hassan, Martin Hendrix, Ph.D., James Laur, Joseph C. Papa, Judith L. Swain, M.D. and Mary Szela) resigned from the board of directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"927d3fae2d","claim":"Mark C. McKenna resigned as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"each of the directors of Prometheus (Mark C. McKenna, Helen C. Adams, Fred Hassan, Martin Hendrix, Ph.D., James Laur, Joseph C. Papa, Judith L. Swain, M.D. and Mary Szela) resigned from the board of directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"92f3933d3e","claim":"Jon Filderman was appointed as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"At the Effective Time, Jon Filderman, Rita Karachun and Aaron Rosenberg, each a director of Merger Sub immediately prior to the Effective Time, became directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"94807c5842","claim":"Fred Hassan resigned as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"each of the directors of Prometheus (Mark C. McKenna, Helen C. Adams, Fred Hassan, Martin Hendrix, Ph.D., James Laur, Joseph C. Papa, Judith L. Swain, M.D. and Mary Szela) resigned from the board of directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"94dafcec65","claim":"Helen C. Adams resigned as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"each of the directors of Prometheus (Mark C. McKenna, Helen C. Adams, Fred Hassan, Martin Hendrix, Ph.D., James Laur, Joseph C. Papa, Judith L. Swain, M.D. and Mary Szela) resigned from the board of directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a0f58ecea0","claim":"Mark C. McKenna departed as Executive Officer at Prometheus Biosciences, Inc..","evidence_excerpt":"Mark C. McKenna, Keith W. Marshall, Ph.D. and Mark Stenhouse ceased to be executive officers of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"aba0f9bf70","claim":"Judith L. Swain, M.D. resigned as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"each of the directors of Prometheus (Mark C. McKenna, Helen C. Adams, Fred Hassan, Martin Hendrix, Ph.D., James Laur, Joseph C. Papa, Judith L. Swain, M.D. and Mary Szela) resigned from the board of directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b893348a40","claim":"Joseph C. Papa resigned as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"each of the directors of Prometheus (Mark C. McKenna, Helen C. Adams, Fred Hassan, Martin Hendrix, Ph.D., James Laur, Joseph C. Papa, Judith L. Swain, M.D. and Mary Szela) resigned from the board of directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bd2461bfed","claim":"Mark Stenhouse departed as Executive Officer at Prometheus Biosciences, Inc..","evidence_excerpt":"Mark C. McKenna, Keith W. Marshall, Ph.D. and Mark Stenhouse ceased to be executive officers of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ddbc7916e1","claim":"James Laur resigned as Director at Prometheus Biosciences, Inc..","evidence_excerpt":"each of the directors of Prometheus (Mark C. McKenna, Helen C. Adams, Fred Hassan, Martin Hendrix, Ph.D., James Laur, Joseph C. Papa, Judith L. Swain, M.D. and Mary Szela) resigned from the board of directors of Prometheus.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f56c3ec630a801d2fb8696dae0b9d012c8c01718","claim":"Prometheus Biosciences, Inc. underwent a change of control involving Merck & Co., Inc. for $200.00 per share in cash (closed 2023-06-16).","evidence_excerpt":"to demand and have properly and validly demanded their appraisal rights under Delaware law, was canceled and extinguished and automatically converted into the right to receive $200.00 per share in cash (the “Merger Consideration”), without interest and subject to any applicable withholding taxes. In addition, at the Effective Time, (i) each outstanding","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Merck & Co., Inc."},{"label":"Consideration","value":"$200.00 per share in cash"},{"label":"Closing","value":"2023-06-16"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}